Altimmune (ALT) Q1 2025 Earnings Call May 13, 2025 08:30 AM ET Speaker0 Good morning, ladies and gentlemen, and welcome to the Altimmune First Quarter twenty twenty five Financial Results Conference Call. After the speakers' presentation, there will be a question and answer session. To ask a question during the session, you will need to press 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press 11 again. As a reminder, this call ...

Core Insights - The company reported a total operating revenue of 1.283 billion yuan in 2024, representing a year-on-year growth of 8.74% [1] - The net profit attributable to shareholders decreased by 6.57% to 189 million yuan [1] - The company continues its dividend policy, proposing a cash dividend of 0.96 yuan per 10 shares, totaling an expected distribution of 40.52 million yuan [2] Revenue Breakdown - Revenue from raw materials reached 988 million yuan, an increase of 11.57% year-on-year [1] - Revenue from formulation products was 161 million yuan, growing by 16.77% year-on-year [1] - Antiviral product revenue decreased by 37.92% due to fluctuations in demand and pricing of oseltamivir [1] - Revenue from antifungal products surged by 60.28% due to increased commercialization demand [1] - Immunosuppressive product revenue grew by 45.72% driven by commercial demand [1] International Expansion - The company experienced a significant 45% increase in overseas revenue, attributed to expanded channels in North America and Europe [1] - The company has established multiple technology platforms to support the development of high-end generics and original new drugs [1] - Products have been registered and authorized for sale in the US, Europe, Japan, South Korea, and countries along the "Belt and Road" initiative, laying a solid foundation for future overseas revenue growth [1] R&D Investment - The company increased its R&D expenditure to 297 million yuan in 2024, a year-on-year increase of 19.65% [2] - Future R&D focus areas include treatments for NASH and dual-target drugs, with a particular emphasis on GLP-1 class drugs in the metabolic field [2] - The company aims to explore new administration methods, multi-target combination therapies, and expand indications to address unmet clinical needs [2] Dividend Policy - The company has maintained a consistent dividend policy since its listing in 2019, with cumulative cash dividends amounting to 246 million yuan over six years [2]